Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.

Bernard V, Lombard-Bohas C, Taquet MC, Caroli-Bosc FX, Ruszniewski P, Niccoli P, Guimbaud R, Chougnet CN, Goichot B, Rohmer V, Borson-Chazot F, Baudin E; French Group of Endocrine Tumors.

Eur J Endocrinol. 2013 Apr 15;168(5):665-74. doi: 10.1530/EJE-12-1101. Print 2013 May.

2.

Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.

Asayama M, Yamada-Murano T, Hara H, Ooki A, Kurosumi M, Yamaguchi K.

Jpn J Clin Oncol. 2014 Feb;44(2):186-90. doi: 10.1093/jjco/hyt193. Epub 2013 Dec 22.

PMID:
24367043
3.

Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.

Fiebrich HB, Siemerink EJ, Brouwers AH, Links TP, Remkes WS, Hospers GA, de Vries EG.

Oncologist. 2011;16(6):783-7. doi: 10.1634/theoncologist.2010-0222. Epub 2011 Apr 11.

4.

Glycemic control in patients with insulinoma treated with everolimus.

Kulke MH, Bergsland EK, Yao JC.

N Engl J Med. 2009 Jan 8;360(2):195-7. doi: 10.1056/NEJMc0806740. No abstract available.

5.

Pasireotide for malignant insulinoma.

Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, Nir K, Talmor Y, Shimon I.

Hormones (Athens). 2016 Apr;15(2):271-6. doi: 10.14310/horm.2002.1639.

6.

Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.

Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG.

Eur J Endocrinol. 2010 May;162(5):1001-8. doi: 10.1530/EJE-09-1010. Epub 2010 Feb 17.

7.

Treatment: symptomatic treatment of hypoglycaemia.

Tabarin A, Goichot B; French Endocrine Society.

Ann Endocrinol (Paris). 2013 Jul;74(3):196-9. doi: 10.1016/j.ando.2013.05.009. Epub 2013 Jun 18. No abstract available.

PMID:
23791453
8.

Malignant metastatic insulinoma-postoperative treatment and follow-up.

Starke A, Saddig C, Mansfeld L, Koester R, Tschahargane C, Czygan P, Goretzki P.

World J Surg. 2005 Jun;29(6):789-93.

PMID:
15880279
9.

New therapeutic options for metastatic malignant insulinomas.

de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA.

Clin Endocrinol (Oxf). 2011 Sep;75(3):277-84. doi: 10.1111/j.1365-2265.2011.04145.x. Review.

PMID:
21649688
10.

Advanced malignant insulinoma. Everolimus response and toxicity.

Cuesta Hernández M, Gómez Hoyos E, Marcuello Foncillas C, Sastre Valera J, Díaz Pérez JÁ.

Endocrinol Nutr. 2014 Jan;61(1):e1-3. doi: 10.1016/j.endonu.2013.06.002. Epub 2013 Aug 30. English, Spanish. No abstract available.

PMID:
23999009
11.

Nocardia brain abscess in a patient treated with everolimus for a metastatic insulinoma.

Walter T, Zadeh G, Hawryluk G, Krzyzanowska MK.

J Clin Oncol. 2013 Feb 20;31(6):e73-5. doi: 10.1200/JCO.2012.42.1982. Epub 2012 Nov 26. No abstract available.

PMID:
23182991
12.

Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.

Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T.

Jpn J Clin Oncol. 2014 May;44(5):479-85. doi: 10.1093/jjco/hyu018. Epub 2014 Mar 30.

PMID:
24688083
13.

Short-term treatment with indinavir fails to reduce the glucose requirement in a patient with malignant insulinoma.

Schütt M, Aries SP, Rosenfeldt M, Peters A, Klein HH.

Am J Med. 2000 Apr 15;108(6):524. No abstract available.

PMID:
10866594
14.

The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia.

Hoff AO, Vassilopoulou-Sellin R.

Cancer. 1998 Apr 15;82(8):1585-92.

PMID:
9554538
15.

Long-term maintenance of normoglycaemia using everolimus in a patient with disseminated insulinoma and severe hypoglycaemia.

Thomas NJ, Brooke AM, Besser GM.

Clin Endocrinol (Oxf). 2013 May;78(5):799-800. doi: 10.1111/cen.12059. No abstract available.

PMID:
23082777
16.

Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma.

Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas-Palomar L, Sánchez-Juan C.

Endocr Pract. 2011 Mar-Apr;17(2):e17-20. doi: 10.4158/EP10282.CR.

PMID:
21247848
17.

A pregnant patient with hypoglycemia.

Mannelli L, Yeh MM, Wang CL.

Gastroenterology. 2012 Oct;143(4):e3-4. doi: 10.1053/j.gastro.2012.03.051. Epub 2012 Aug 23. No abstract available.

PMID:
22921669
18.

Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature.

Scharf M, Mueller D, Koenig U, Pfestroff A, Nimphius W, Figiel J, Rinke A, Koenig A, Gress T.

Pancreatology. 2014 Nov-Dec;14(6):542-5. doi: 10.1016/j.pan.2014.07.011. Epub 2014 Jul 26.

PMID:
25459566
19.

Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma.

Chandra P, Yarandi SS, Khazai N, Jacobs S, Umpierrez GE.

Am J Med Sci. 2010 Nov;340(5):414-7. doi: 10.1097/MAJ.0b013e3181ee7be2.

PMID:
20724903
20.

[Malignant insulinoma is a rare cause of hypoglycemia].

Fokdal LU, Hansen F.

Ugeskr Laeger. 2003 Mar 31;165(14):1462-3. Danish.

PMID:
12715679

Supplemental Content

Support Center